公司资料
Anebulo Pharmaceuticals 股价、新闻与催化剂
- 股票代码:
- ANEB
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.33 USD (-5.69%)
收盘价
最后更新: 2026年8月21日
—
市值
股价为何变动
Current closing-price context is not available for ANEB.
公司概览
Cannabis-Toxicity Antidote
Anebulo Pharmaceuticals develops a specific treatment for acute cannabis-induced toxicity in adults and children. The company’s approach directly blocks the cannabinoid receptor responsible for many central effects of THC.
Selonabant
Selonabant, or ANEB-001, is a small-molecule CB1 receptor antagonist. Oral selonabant blocked or reversed key THC effects in a controlled Phase 2 proof-of-concept study in healthy adults.
Pediatric Intravenous Strategy
Anebulo is prioritizing an intravenous formulation for pediatric cannabis poisoning rather than moving the adult oral product directly into Phase 3. The company has scaled the IV formulation and initiated a Phase 1 single-ascending-dose safety study.
未来催化剂
- Anebulo's story is now centered on selonabant and the company's decision to step away from Nasdaq. That makes the next chapter feel more like a value-maximization exercise around a finished Phase 2 asset than a broad public-development story.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。